← All trials
NCT06285617
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2024
- Primary completion
- Jan 31, 2025
- Completion date
- Apr 30, 2025
- First posted
- Feb 29, 2024
- Last posted
- Feb 29, 2024
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.